XOMAO

$25.39

Post-MarketAs of Mar 17, 8:00 PM UTC

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$25.39
Potential Downside
11.3%
Whystock Fair Value$22.51
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commerc...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.36
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Strong income play. Yield provides a meaningful total return floor.
826.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
22.45%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.28

Recent News

Simply Wall St.
Jan 18, 2026

Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses

Key Insights Given the large stake in the stock by institutions, XOMA Royalty's stock price might be vulnerable to...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Dec 21, 2025

XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years

XOMA Royalty Corporation ( NASDAQ:XOMA ) shareholders might understandably be very concerned that the share price has...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
24/7 Wall St.
Dec 12, 2025

Huge Insider Buying in MGM and Salesforce

As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investor's Business Daily
Dec 11, 2025

Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug

Xoma stock plummeted Thursday after its partner, Rezolute, said its treatment for hyperinsulinism failed in Phase 3 testing.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Nov 19, 2025

XOMA Royalty's (NASDAQ:XOMA) Earnings Aren't As Good As They Appear

Strong earnings weren't enough to please XOMA Royalty Corporation's ( NASDAQ:XOMA ) shareholders over the last week...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.